Q-omics provides the consensus-scored TSGA13 profile across patient tissues and cancer cell-line models. TSGA13 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, TSGA13 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, TSGA13 RNA expression shows 6,652 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PAAD, KIRP, and STAD as cancer lineages where TSGA13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSGA13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSGA13 survival associations across molecular data types. TSGA13 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSGA13 RNA expression–survival associations across cancer types. High TSGA13 expression shows unfavorable associations in SKCM, LUSC, COAD and BLCA, but favorable associations in PAAD and UCS. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for TSGA13 RNA expression.
This table summarizes TSGA13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TSGA13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSGA13 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRP, BLCA, PRAD and LUSC. The KIRP box plot shows higher TSGA13 RNA expression in tumor versus normal tissue (log2 FC = +0.047, t-test p = .017).
This table shows molecular features associated with TSGA13 in patient tissues and cancer cell lines. In patient samples, TSGA13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TSGA13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
